Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro)

Annals of Oncology

Volumn 25, Issue 1, 2014, Pages 81-89

  von Minckwitz, G ^a,b   Rezai, M ^c   Fasching, P A ^d   Huober, J ^e   Tesch, H ^f   Bauerfeind, I ^g   Hilfrich, J ^h   Eidtmann, H ⁱ   Gerber, B ^j   Hanusch, C ^k   Blohmer, J U ^l   Costa, S D ^m   Jackisch, C ⁿ   Paepke, S ^o   Schneeweiss, A ^p   Kummel S ^q   Denkert, C ^r   Mehta, K ^a   Loibl, S ^a,n   Untch, M ^s  

^a GERMAN BREAST GROUP   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Breast Center   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f Bethanien Krankenhaus Frankfurt   (Germany)

^g Klinikum Landshut   (Germany)

^h Eilenriedeklinik   (Germany)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^j ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^k Klinikum Zum Roten Kreuz   (Germany)

^l MARTIN LUTHER KRANKENHAUS   (Germany)

^m UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁿ Klinikum Offenbach   (Germany)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^q KLINIKEN ESSEN MITTE   (Germany)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^s HELIOS KLINIKUM BERLIN BUCH   (Germany)

more..

Author keywords

Capecitabine; Disease free survival; Neoadjuvant chemotherapy; Overall survival; Trastuzumab

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; TRASTUZUMAB;

ADD ON THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; FEMALE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HER2 NEGATIVE BREAST CANCER; HER2 POSITIVE BREAST CANCER; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME;

CAPECITABINE; DISEASE-FREE SURVIVAL; NEOADJUVANT CHEMOTHERAPY; OVERALL SURVIVAL; TRASTUZUMAB;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; TAXOIDS; TREATMENT OUTCOME;

EID: 84905375861     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt410     Document Type: Article

References (13)

1. von Minckwitz G, Untch M, Blohmer JU et al. Definition and impact of pathological complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
2. Cortazar P, Zhang L, Untch M et al. Meta-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). San Antonio Breast Cancer Conference San Antonio Texas, USA 2012; S1-S11.
3. O'Shaughnessy J, Paul D, Stokoe C et al. First efficacy results of a randomized, open-label, phase II study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without capecitabine, in high-risk early breast cancer. Cancer Res 2010; 70(24 Suppl): Abstract # S4-2.
4. von Minckwitz G, Blohmer JU, Costa SD et al. Response-Guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol; doi: 10.1200/JCO.2012.45.0940.
5. von Minckwitz G, Rezai M, Loibl S et al. Capecitabine in addition to anthracycline/ taxane-based neoadjuvant treatment in patients with primary breast cancer: The Phase III GeparQuattro Study. J Clin Oncol 2010; 28: 2015-2023.
6. Huober J, von Minckwitz G, Denkert C et al. Effect of neoadjuvant anthracyclinetaxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 2010; 124: 133-140.
7. Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from GeparQuatro Study. J Clin Oncol 2010; [28:] 2024-2031.
8. Jiang Y, Yin W, Zhou L et al. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis. PLoS One 2012; 7(3): e32474.
9. von Minckwitz G, Zahm MD, Eidtmann H et al. Zoledronic acid (ZOL) as add on therapy in patients with tumor residuals after neoadjuvant chemotherapy for primary breast cancer-first interim safety analysis of the NATAN study (GBG 36). Breast Cancer Symposium, Proceeding Book 2009; Abstract # 216, ASCO Breast 2009.
10. Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-2132.
11. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012; 30: 11-18.
12. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol 2009; 10: 1145-1151.
13. von Minckwitz G, Untch M, Nüesch E et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125: 145-156.